Hiroo Matsuo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hiroo Matsuo has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Satoshi Kutsuna
Department of Infection Control, Graduate School of Medicine Faculty of Medicine, Osaka University
4 shared publications Satoshi Kutsuna
3 shared publications- Daisuke Onozuka
Center for Advanced Modalities and DDS (CAMaD), The University of Osaka, Osaka, Japan
2 shared publications - Keiji Konishi
AIDS Medical Center, NHO Osaka National Hospital, Osaka, Japan
2 shared publications - Yoshiki Kusama
Department of Infectious Diseases, University of Osaka Hospital, Osaka, Japan
2 shared publications - Hisao Yoshida
Department of Infection Control and Prevention, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan
1 shared publication
Latest Publications
- Open Access
- 4 July 2026
- Published by Elsevier in CMI Communications
- Vol. 3 (3)
Impact of Blood Culture Bottle Shortage on Blood Culture Positivity Rates in Japan: A Nationwide Hospital-Based Study
- 4 July 2026
- Published by Elsevier in CMI Communications
- Vol. 3 (3)
Open AccessImpact of Blood Culture Bottle Shortage on Blood Culture Positivity Rates in Japan: A Nationwide Hospital-Based Study
- Open Access
- 19 January 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 164, 108410
Tumor-like scalp lesions in a patient with ocular syphilis
- 19 January 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 164, 108410
Open AccessTumor-like scalp lesions in a patient with ocular syphilis
- Open Access
- 15 September 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (10)
Pulmonary Infection Due to Trametes elegans and Peniophora incarnata
Recent environmental changes and advances in modern medicine—particularly the increasing use of immunosuppressive therapies and organ transplantation—have led to a growing number of infections caused by fungi that were previously not recognized as human pathogens. We report a case of pulmonary infection caused by Trametes elegans and Peniophora incarnata in a 27-year-old man with advanced acquired immunodeficiency syndrome who presented with multiple bilateral pulmonary nodules. Both fungi, which are rare environmental homobasidiomycetes, were identified using molecular methods. Thermal tolerance was demonstrated by T. elegans, supporting its ability to proliferate in human lungs, while P. incarnata showed limited growth at 35 °C. Initial treatment with liposomal amphotericin B was ineffective; however, the patient's condition improved following a switch to voriconazole. Climate change may increase the incidence of such opportunistic infections in individuals with compromised immunity.
- 15 September 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (10)
Open AccessPulmonary Infection Due to Trametes elegans and Peniophora incarnata
Recent environmental changes and advances in modern medicine—particularly the increasing use of immunosuppressive therapies and organ transplantation—have led to a growing number of infections caused by fungi that were previously not recognized as human pathogens. We report a case of pulmonary infection caused by Trametes elegans and Peniophora incarnata in a 27-year-old man with advanced acquired immunodeficiency syndrome who presented with multiple bilateral pulmonary nodules. Both fungi, which are rare environmental homobasidiomycetes, were identified using molecular methods. Thermal tolerance was demonstrated by T. elegans, supporting its ability to proliferate in human lungs, while P. incarnata showed limited growth at 35 °C. Initial treatment with liposomal amphotericin B was ineffective; however, the patient's condition improved following a switch to voriconazole. Climate change may increase the incidence of such opportunistic infections in individuals with compromised immunity.
- Open Access
- 21 August 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (9) , ofaf517
Opsoclonus-myoclonus-ataxia Syndrome in an ART-naïve Patient With CSF/Plasma HIV-1 RNA Discordance
Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare neuroimmunological disorder with diverse etiologies, including infection-associated triggers such as human immunodeficiency virus (HIV) infection. Herein, we report a case of HIV-associated OMAS in an antiretroviral therapy (ART)-naïve patient who presented with cerebrospinal fluid (CSF)/plasma HIV-1 RNA discordance. A 16-year-old female was diagnosed with HIV following the onset of OMAS. The CSF HIV-1 RNA level was higher than that in the plasma. After ART initiation, both the CSF HIV viral load and OMAS symptoms improved simultaneously. This case demonstrates that CSF/plasma HIV-1 RNA discordance can occur in ART-naïve patients with HIV-associated OMAS. Moreover, our findings suggest that, in such cases, viral suppression through ART alone may be sufficient to achieve clinical resolution without the need for adjunctive immunosuppressive therapy.
- 21 August 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (9) , ofaf517
Open AccessOpsoclonus-myoclonus-ataxia Syndrome in an ART-naïve Patient With CSF/Plasma HIV-1 RNA Discordance
Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare neuroimmunological disorder with diverse etiologies, including infection-associated triggers such as human immunodeficiency virus (HIV) infection. Herein, we report a case of HIV-associated OMAS in an antiretroviral therapy (ART)-naïve patient who presented with cerebrospinal fluid (CSF)/plasma HIV-1 RNA discordance. A 16-year-old female was diagnosed with HIV following the onset of OMAS. The CSF HIV-1 RNA level was higher than that in the plasma. After ART initiation, both the CSF HIV viral load and OMAS symptoms improved simultaneously. This case demonstrates that CSF/plasma HIV-1 RNA discordance can occur in ART-naïve patients with HIV-associated OMAS. Moreover, our findings suggest that, in such cases, viral suppression through ART alone may be sufficient to achieve clinical resolution without the need for adjunctive immunosuppressive therapy.
- Open Access
- 3 February 2025
- Published by MDPI AG in Preprints.org
Knowledge, Attitudes, and Practices Regarding the COVID-19 Vaccine for Children: A Questionnaire Survey at the 18-Month Health Check-Up
Background/Objectives: COVID-19 vaccination rate among children in Japan is low. This study aimed to address the knowledge, attitudes, and practices (KAP) regarding parental COVID-19 vaccine acceptance and hesitancy among parents with infants. Methods: We conducted a paper-based, household. Survey asked COVID-19 vaccination status, knowledge and attitudes among households with a vaccinated child, knowledge and attitudes among households with a non-vaccinated child, and intention to vaccinate among households with a non-vaccinated child. To analyze the factors associated with parental behavior, univariate and multivariate analyses were performed. Results: Response sheets were mailed to 1,060 households, and 960 children; and 665 respondents agreed to participate in the study. Only 3.8% of the children received the COVID-19 vaccine. In the multivariate analysis, parents who received three or more doses of the COVID-19 vaccine was associated with the child’s vaccination status (adjusted OR 8.24, p < 0.01). Among respondents with a vaccinated child, 28.0% and 28.0% answered that vaccines can prevent long-term effects and complications and that COVID-19 is a serious infection, respectively. Sixteen percent said that social media platforms influenced their decision to vaccinate. Among the respondents with a non-vaccinated child, 38.9% answered that they had insufficient data on vaccine safety, while 26.7% answered that television and online news influenced their decision. Only 1.2% answered that they were planning to get the COVID-19 vaccine in the future. Conclusions: This KAP survey found a low rate of vaccination against COVID-19 among infants. These findings will contribute to the formulation of future public health practices.
- 3 February 2025
- Published by MDPI AG in Preprints.org
Open AccessKnowledge, Attitudes, and Practices Regarding the COVID-19 Vaccine for Children: A Questionnaire Survey at the 18-Month Health Check-Up
Background/Objectives: COVID-19 vaccination rate among children in Japan is low. This study aimed to address the knowledge, attitudes, and practices (KAP) regarding parental COVID-19 vaccine acceptance and hesitancy among parents with infants. Methods: We conducted a paper-based, household. Survey asked COVID-19 vaccination status, knowledge and attitudes among households with a vaccinated child, knowledge and attitudes among households with a non-vaccinated child, and intention to vaccinate among households with a non-vaccinated child. To analyze the factors associated with parental behavior, univariate and multivariate analyses were performed. Results: Response sheets were mailed to 1,060 households, and 960 children; and 665 respondents agreed to participate in the study. Only 3.8% of the children received the COVID-19 vaccine. In the multivariate analysis, parents who received three or more doses of the COVID-19 vaccine was associated with the child’s vaccination status (adjusted OR 8.24, p < 0.01). Among respondents with a vaccinated child, 28.0% and 28.0% answered that vaccines can prevent long-term effects and complications and that COVID-19 is a serious infection, respectively. Sixteen percent said that social media platforms influenced their decision to vaccinate. Among the respondents with a non-vaccinated child, 38.9% answered that they had insufficient data on vaccine safety, while 26.7% answered that television and online news influenced their decision. Only 1.2% answered that they were planning to get the COVID-19 vaccine in the future. Conclusions: This KAP survey found a low rate of vaccination against COVID-19 among infants. These findings will contribute to the formulation of future public health practices.
- 12 November 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (2) , 102557
Current management and awareness of hepatitis coinfection in HIV care: A single-center retrospective study in Japan
- 12 November 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (2) , 102557
Current management and awareness of hepatitis coinfection in HIV care: A single-center retrospective study in Japan
- Open Access
Protocol for a Randomized, Open-Label Clinical Trial on the Effect of Mouthwash on Salivary SARS-CoV-2 Load
Mouthwashes containing cetylpyridinium chloride (CPC) or on-demand aqueous chlorine dioxide (ACD) have potential to reduce the salivary severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) load in individuals with SARS-CoV-2 infection. This study will evaluate the effect of CPC and on-demand ACD mouthwashes on salivary SARS-CoV-2 levels in individuals with acute asymptomatic or mild SARS-CoV-2 infection (COVID-19) staying in a residential recuperation facility in Osaka, Japan. This randomized, open-label clinical trial will include three equal-sized groups (CPC mouthwash, on-demand ACD mouthwash, and placebo), with 30 participants per group. A stratified replacement block method will be used to ensure balanced allocation based on symptom presence and days since symptom onset. Participants will use mouthwash at set times for 7 days or until the end of recuperation. Saliva samples will be collected at multiple time points and tested for SARS-CoV-2 using quantitative reverse transcription polymerase chain reaction. The primary outcome will be changes in salivary SARS-CoV-2 viral load 2 h after the first mouthwash use compared with the pre-mouthwash level. Secondary outcomes will include changes in salivary viral load and clinical parameters at different time points. This study was registered with the Japan Registry of Clinical Trials on 18 October 2022 (jRCTs051220107).
Open AccessProtocol for a Randomized, Open-Label Clinical Trial on the Effect of Mouthwash on Salivary SARS-CoV-2 Load
Mouthwashes containing cetylpyridinium chloride (CPC) or on-demand aqueous chlorine dioxide (ACD) have potential to reduce the salivary severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) load in individuals with SARS-CoV-2 infection. This study will evaluate the effect of CPC and on-demand ACD mouthwashes on salivary SARS-CoV-2 levels in individuals with acute asymptomatic or mild SARS-CoV-2 infection (COVID-19) staying in a residential recuperation facility in Osaka, Japan. This randomized, open-label clinical trial will include three equal-sized groups (CPC mouthwash, on-demand ACD mouthwash, and placebo), with 30 participants per group. A stratified replacement block method will be used to ensure balanced allocation based on symptom presence and days since symptom onset. Participants will use mouthwash at set times for 7 days or until the end of recuperation. Saliva samples will be collected at multiple time points and tested for SARS-CoV-2 using quantitative reverse transcription polymerase chain reaction. The primary outcome will be changes in salivary SARS-CoV-2 viral load 2 h after the first mouthwash use compared with the pre-mouthwash level. Secondary outcomes will include changes in salivary viral load and clinical parameters at different time points. This study was registered with the Japan Registry of Clinical Trials on 18 October 2022 (jRCTs051220107).